Today, we bring you a conversation on the use of continuous glucose monitoring technology (CGM) and its transformer potential in diabetes care.
Davida Kruger, NP, certified practitioner nurse in Henry Ford in the Division of Endocrinology, was maintained:
- Jaime Murillo, MD, main vice-president and chief doctor, medical affairs, United Health Group
- Jeremy Wigginton, MD, chief doctor of a regional blue plan
- Ian Neeland, MD, Director of cardiovascular prevention, Harrington Health and Vascular Institute and Associate Medicine Harrington Harrington Hospitals, Case Western Reserve University School of Medicine
- Ken Cohen, MD, Executive Director of Translational Research, Optum Health.
The subjects of conversation for today’s podcast include the way in which the CGM addresses therapeutic inertia, improves glycemic control and leads to improvements in the results of patients and the efficiency of health care, as well as obstacles to adoption, strategies for enlargement of access and profitability of the CGM implementation.
While the use of CGMs began with patients with type 1 diabetes, it went to use in type 2 diabetes, said Neeland. CGM allows “more real and faster therapeutic interventions,” added Wigginton.
“I think we all know that the CGM in the good patient population with the right doctor and the right care team managing that data can absolutely improve clinical inertia to previous intervention (and) better results for patients,” he said. “I think it’s a well -known fact that it can happen.”
The CGM can provide several measures beyond the simple real glucose, and as technology provides an instantaneous data from 10 to 14 days, it provides average glucose, time in the range, the glucose management indicator and the variability of glucose. These measures are also playing a role in data on the effectiveness of health care and information measures and quality objectives for responsible care organizations, noted Cohen.
However, there are variable coverage policies for CGMs that have an impact on patient access and results.
“Health plans must further normalize their coverage decisions, which must be done according to medicine based on evidence,” said Murillo. “There is this perception that health plans make unilateral decisions based on their own convenience. The reality is that all of these coverage decisions should be based on evidence. ”
Listen above or through one of these Podcast services: